This company listing is no longer active
5MP0 Stock Overview
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.04 |
| 52 Week High | UK£2.50 |
| 52 Week Low | UK£0.01 |
| Beta | 1.13 |
| 1 Month Change | -76.71% |
| 3 Month Change | 304.00% |
| 1 Year Change | -98.38% |
| 3 Year Change | -99.40% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.2% | -1.5% | 1.9% |
| 1Y | -98.4% | -23.6% | 4.6% |
Return vs Industry: 5MP0 underperformed the German Biotechs industry which returned -7% over the past year.
Return vs Market: 5MP0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 5MP0 volatility | |
|---|---|
| 5MP0 Average Weekly Movement | 542.1% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5MP0's share price has been volatile over the past 3 months.
Volatility Over Time: 5MP0's weekly volatility has increased from 321% to 542% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 20 | Stephen Stamp | www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
Biodexa Pharmaceuticals Plc Fundamentals Summary
| 5MP0 fundamental statistics | |
|---|---|
| Market cap | €4.01m |
| Earnings (TTM) | -€6.06m |
| Revenue (TTM) | €728.56k |
5.5x
P/S Ratio-0.7x
P/E RatioIs 5MP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MP0 income statement (TTM) | |
|---|---|
| Revenue | UK£645.00k |
| Cost of Revenue | UK£4.65m |
| Gross Profit | -UK£4.01m |
| Other Expenses | UK£1.36m |
| Earnings | -UK£5.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | -621.55% |
| Net Profit Margin | -832.09% |
| Debt/Equity Ratio | 0% |
How did 5MP0 perform over the long term?
See historical performance and comparison